MeMed Diagnostics aims to prevent antibiotics misuse, which costs healthcare systems tens of billions of dollars annually, by developing immuno-personalized diagnosis devices that distinguish between bacterial and viral infections based on patients' immune responses. Their platform, ImmunoDx™, combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection, enabling physicians to make informed antibiotic treatment decisions. MeMed Diagnostics is a leading med tech and bio-convergence company that translates the complex signals of the immune system into simple diagnostic insights to improve patient outcomes.